(0.09%) 5 308.13 points
(-0.49%) 39 807 points
(0.65%) 16 795 points
(-0.10%) $79.72
(-0.33%) $2.74
(-0.16%) $2 434.50
(0.26%) $32.51
(-0.61%) $1 057.20
(0.02%) $0.921
(0.04%) $10.70
(-0.03%) $0.787
(0.02%) $90.69
Live Chart Being Loaded With Signals
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury...
Stats | |
---|---|
今日成交量 | 174 049 |
平均成交量 | 171 620 |
市值 | 5.45M |
EPS | $0 ( 2024-05-14 ) |
下一个收益日期 | ( $-0.220 ) 2024-07-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0300 |
ATR14 | $0.00500 (1.81%) |
音量 相关性
Portage Biotech Inc. 相关性 - 货币/商品
Portage Biotech Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-1 000.00 (0.00 %) |
EPS: | $-6.49 |
FY | 2023 |
营收: | $0 |
毛利润: | $-1 000.00 (0.00 %) |
EPS: | $-6.49 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-1.470 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.350 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Portage Biotech Inc.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。